
Teleflex (TFX) Stock Forecast & Price Target
Teleflex (TFX) Analyst Ratings
Bulls say
Teleflex is poised for a positive outlook due to projected sales growth of at least 6% from a nearly $1 billion base, driven by the combined performance of its interventional business and anticipated revenue from acquired products. The company is expected to achieve moderate operating margin improvement and double-digit earnings growth, supported by strong revenue growth and cost reduction initiatives. Additionally, the firm’s growth potential is reinforced by a favorable product mix shift, ongoing new product launches, and the likelihood of accretive acquisitions, which collectively reinforce a positive earnings trajectory.
Bears say
Teleflex's recent financial performance has contributed to a negative outlook for its stock, highlighted by a significant share price decline of 22% following the release of its fourth-quarter 2024 results and disappointing 2025 guidance. The company has faced challenges such as missing consensus revenue expectations and projecting lower-than-expected growth rates, particularly in its UroLift product line and other key segments, leading to a revised 2025 earnings per share estimate of $14.17. Additionally, the planned acquisition of Biotronik's Vascular Intervention business for approximately $820 million has raised concerns about potential risks associated with larger acquisitions, including dilution of earnings per share.
This aggregate rating is based on analysts' research of Teleflex and is not a guaranteed prediction by Public.com or investment advice.
Teleflex (TFX) Analyst Forecast & Price Prediction
Start investing in Teleflex (TFX)
Order type
Buy in
Order amount
Est. shares
0 shares